Obesity in primary antiphospholipid syndrome is associated with worse outcome

Caldas, Cézar Augusto Muniz; Mota, Lícia Maria Henrique da; Carvalho, Jozélio Freire de

doi:10.1016/j.jbspin.2010.12.003

Cited by 13 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result disagree with Caldas et al (2010) who reported that there is no significant difference in age and duration of the disease between obese and non obese group P value is 0.78 and 0.78. Table 1 also shows that there is no significant difference in obstetric event between obese and non obese group (P value in case of REM is 0.656, in case of PMB is 0.181 and in IUFD is 0.179. this result disagree with Caldas et al (2010) who reported that obese group had a higher frequency of obstetric event 53.3% than non obese group 22.8% p value 0.04. This table also shows that there is no significant difference in the incidence PTE between obese and non obese group 43.3% and 28.3% respectively P value is 0.165.…”

Section: Discussioncontrasting

confidence: 90%

Obesity as Environmental Risk Factor for Repeated Pregnancy Loss in Patients With Antiphospholipid Syndrome

El-Bokary

Azza³

2018

Journal of Environmental Science

View full text Add to dashboard Cite

Introduction: Antiphospholidsyndrome (APS) is an autoimmune hypercoagulablestate caused by antiphospholid antibodies. Primary antiphospholipidsyndrome occurs in absence of any other related disease. Secondary antiphospholipid syndrome occurs with other autoimmune disease as systemic lupus erythrematosis. The clinical features of the APS are various, but the most common clinical presentation is pregnancy loss, DVT. Pulmonary thromboembolism, the cardiac manifestations of APS include myocardial infarction, pericardial effusion, myocardiopathy, and coronary artery thrombosis, but the most common manifestation is valvular abnormalities. Aim: to investigate the influence of obesity in women diagnosed as an antiphospholipid cases according to Sydney's criteria on pregnancy morbidities, vascular events, pulmonary thromboemboism and laboratory criteria. Methods: A case control study was conducted that include women attending obstetric outpatient clinic. These women were previously diagnosed as antiphospholipid cases according to (Sydney's criteria).A total of 60 women have been equally divided into two groups: First group corresponds to control group which includes 30 women with normal body mass index (BMI) i.e. < 30 Kg/m2 and, second group include 30 obese women with (BMI > 30Kg/m2). Results: Obesity is independent predictor for preterm birth intrauterine fetal death and pulmonary thromboembolism.

show abstract

Section: Discussioncontrasting

confidence: 90%

Obesity as Environmental Risk Factor for Repeated Pregnancy Loss in Patients With Antiphospholipid Syndrome

El-Bokary

Azza³

2018

Journal of Environmental Science

View full text Add to dashboard Cite

show abstract

“…This concern with the nutritional status of the patient is, in turn, even more valued in the course of a pregnancy due to the risk of maternal and fetal complications that obesity can cause. Considering such losses, this is one of the main risk factors that must be fought in individuals with APS [38, 39]. A study by Caldas et al showed worse prognosis in obese patients with primary APS compared with those who were not obese.…”

Section: Traditional Risk Factorsmentioning

confidence: 99%

“…In this transversal work, 50 patients with primary APS were divided into 2 groups: APS obese (BMI ≥ 30 kg/m 2 ) and APS nonobese (BMI < 30 kg/m 2 ). The obese group had a higher frequency of pulmonary embolism (PE) and obstetric events [38]. …”

Section: Traditional Risk Factorsmentioning

confidence: 99%

Cardiovascular Risk Factors in the Antiphospholipid Syndrome

Silva

Levy

Carvalho

2014

Journal of Immunology Research

Self Cite

View full text Add to dashboard Cite

A major cause of morbidity and mortality in the context of the antiphospholipid syndrome (APS) is the occurrence of thrombotic events. Besides the pathogenic roles of antiphospholipid antibodies (aPL), other risk factors and medical conditions, which are conditions for traditional risk of an individual without the APS, can coexist in this patient, raising their risk of developing thrombosis. Therefore, the clinical and laboratory investigation of comorbidities known to increase cardiovascular risk in patients with antiphospholipid antibody syndrome is crucial for the adoption of a more complete and effective treatment. Experimental models and clinical studies show evidence of association between APS and premature formation of atherosclerotic plaques. Atherosclerosis has major traditional risk factors: hypertension, diabetes mellitus, obesity, dyslipidemia, smoking, and sedentary lifestyle that may be implicated in vascular involvement in patients with APS. The influence of nontraditional risk factors as hyperhomocysteinemia, increased lipoprotein a, and anti-oxLDL in the development of thromboembolic events in APS patients has been studied in scientific literature. Metabolic syndrome with all its components also has been recently studied in antiphospholipid syndrome and is associated with arterial events.

show abstract

“…An article published by Caldas et al demonstrated an increased mortality rate in obese patients with APS. In this study, APS individuals with a higher body mas index (BMI) of >30 were found to have a greater incidence of life-threatening complications, such as PE, compared to APS individuals with a lower BMI of <30 [9]. Other reasons for premature atherosclerosis include the presence of atherosclerosis inducing APL antibodies, mainly lupus anticoagulant, anticardiolipin antibody, IgG antibodies against beta-2glycoprotein antibody, and prothrombin.…”

Section: Probable Caps Diagnosismentioning

confidence: 83%